ArticlePilot and feasibility studies2026
Suprachoroidal VIsco-bucKlING versus gas tamponade for the treatment of rhegmatogenous retinal detachment (VIKING): study protocol for a multi-centre, randomised, controlled feasibility study.
Article in Pilot and feasibility studies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04557527 (Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment: A Randomized, Controlled, Feasibility Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRhegmatogenous retinal detachment (RRD) is a potentially blinding condition that affects ~ 1 in 10,000 adults per year. Retinal detachment surgery usually involves internal reapposition of the retina using the injection of a gas tamponade into the vitreous cavity. However, this has downsides including delayed visual recovery, the need to posture postoperatively, limiting fundal view during postoperative monitoring, and the risk of raised intraocular pressure. We examine a novel surgical variation, using a temporary suprachoroidal viscobuckle (SCVB) instead of gas. SCVB involves the controlled injection of high viscosity viscoelastic through an external scleral incision into the suprachoroidal space to create an indent under a causative retinal break. The sodium hyaluronate viscoelastic is resorbed over 2-3 weeks, long enough for intraoperative laser retinopexy to cause chorioretinal adhesion. The primary objective of this study is to establish if it is feasible to recruit, retain, and evaluate patients with RRD into a larger randomised controlled trial of SCVB. Secondary objectives are to make a preliminary assessment of safety and efficacy.
methodsThis multicentre, randomised, controlled, two-group, unmasked feasibility trial recruits participants with primary RRD and a break or breaks within 1 clock hour. The CE-marked sodium hyaluronate viscobuckle is created during otherwise standard pars plana vitrectomy RRD surgery. Feasibility outcomes include screen failure rate, rate of recruitment, protocol compliance, and participant retention. The main efficacy outcome is retinal attachment with no intravitreal tamponade present and no subretinal fluid which could spread, without the need for further surgery, at week 12. The key secondary efficacy outcome is Early Treatment of Diabetic Retinopathy Study best-corrected visual acuity at week 24. Safety is recorded through adverse events and serious adverse events. DISCUSSION: SCVB has multiple potential advantages for patients. This study will help determine if a definitive study of SCVB is justified and deliverable and inform its design.
trial registrationClinicalTrials.gov Identifier: NCT04557527, registered 09 September 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.